Clinical Trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2023-08-14; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2023-12-13
Trial Details
NCT Number NCT06001788
Lead Sponsor Kura Oncology, Inc.
Conditions AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia +4 more
Enrollment 171 participants
Start Date 2024-02-22
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-14